126 related articles for article (PubMed ID: 20121334)
21. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
22. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
23. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
25. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
26. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
27. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
Hölscher G; Anthuber C; Bastert G; Burges A; Mayr D; Oberlechner E; Schubert-Fritschle G; Sinz S; Sommer H; Schmalfeldt B; Engel J;
Acta Obstet Gynecol Scand; 2009; 88(4):440-8. PubMed ID: 19191075
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
[TBL] [Abstract][Full Text] [Related]
29. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
30. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study.
Polterauer S; Grimm C; Seebacher V; Concin N; Marth C; Tomovski C; Husslein H; Leipold H; Hefler-Frischmuth K; Tempfer C; Reinthaller A; Hefler L
Oncologist; 2009 Oct; 14(10):979-85. PubMed ID: 19776095
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
33. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
35. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
36. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
[TBL] [Abstract][Full Text] [Related]
37. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
[TBL] [Abstract][Full Text] [Related]
39. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
Kang S; Seo SS; Park SY
J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
[TBL] [Abstract][Full Text] [Related]
40. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]